Crossref
CAR-ving away OX40L with engineered T regs
Science Immunology · 2024
DOI: 10.1126/sciimmunol.adu0983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Jonathan S Maltzman. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, OX40 Ligand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
OX40L–CAR-T regs show promise for treating autoimmunity and transplantation rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
T-Lymphocytes, RegulatoryOX40 LigandHumansAnimalsGraft RejectionReceptors, Chimeric AntigenImmunotherapy, Adoptive
Substanzen
OX40 LigandReceptors, Chimeric AntigenTNFSF4 protein, human
Autor:innen und Institutionen
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Geriatric Research and Education and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA, USA.
ORCID-Profile: Jonathan S Maltzman
Zitieren
APA
Maltzman, J. S. (2024). CAR-ving away OX40L with engineered T regs. Science Immunology. https://doi.org/10.1126/sciimmunol.adu0983
Vancouver
Maltzman JS. CAR-ving away OX40L with engineered T regs. Science Immunology. 2024. doi:10.1126/sciimmunol.adu0983
BibTeX
@article{Maltzman2024,
author = {Maltzman, Jonathan S},
title = {CAR-ving away OX40L with engineered T regs},
journal = {Science Immunology},
year = {2024},
doi = {10.1126/sciimmunol.adu0983}
}
EUVIMED